DGIdb - FP-1039 Drug Record

FP-1039 chembl:CHEMBL4297755 Antineoplastic

Alternate Names:

GSK3052230
FP-1039
HGS1036
GSK-3052230

Drug Info:

FDA Approval	not approved
Drug Class	fusion protein
Drug Indications	antineoplastic agent

(2 More Sources)

Publications:

Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med
Szlachcic A et al., 2012, FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation., Int J Nanomedicine

FP-1039 FGFR1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

Indication/Tumor Type lung cancer

PMIDs:
23226697 23536011

Sources:
TdgClinicalTrial JAX-CKB TTD
FP-1039 FGFR2

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
23536011

Sources:
TdgClinicalTrial JAX-CKB
FP-1039 FGF2

Interaction Score: 0.59

Interaction Types & Directionality:

suppressor (inhibitory)

Interaction Info:

Notes Targets other FGF ligands as well

PMIDs:
None found

Sources:
TALC
FP-1039 FGFR4

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
FP-1039 FGFR3

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

TdgClinicalTrial: FP-1039
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class fusion protein

FDA Approval not approved

Publications:
TTD: FP-1039
- Version: 2020.06.01
Alternate Names:

D0U2DO TTD Drug ID

Drug Info:

Publications:

Szlachcic A et al., 2012, FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation., Int J Nanomedicine
JAX-CKB: GSK3052230
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med
TTD: GSK3052230
- Version: 2020.06.01
Alternate Names:

D0P0LT TTD Drug ID

Drug Info:

Publications:
TALC: GSK3052230
- Version: 12-May-2016
Alternate Names:

GSK3052230 Primary Drug Name

GSK3052230 Drug Synonym

FP-1039 Drug Synonym

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL4297755
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	FP-1039
Novel drug target	Established target
Indication/Tumor Type	lung cancer

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

GSK3052230	Primary Drug Name
GSK3052230	Drug Synonym
FP-1039	Drug Synonym

FP-1039 Drug Record

FP-1039 chembl:CHEMBL4297755 Antineoplastic

Alternate Names:

Drug Info:

Publications:

FP-1039 FGFR1

Interaction Types & Directionality: n/a

Interaction Info: Trial Name FP-1039 Novel drug target Established target Indication/Tumor Type lung cancer

PMIDs: 23226697 23536011

Sources: TdgClinicalTrial JAX-CKB TTD

FP-1039 FGFR2

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 23536011

Sources: TdgClinicalTrial JAX-CKB

FP-1039 FGF2

Interaction Types & Directionality: suppressor (inhibitory)

Interaction Info: Notes Targets other FGF ligands as well

PMIDs: None found

Sources: TALC

FP-1039 FGFR4

Interaction Types & Directionality: n/a

Interaction Info: Trial Name FP-1039 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

FP-1039 FGFR3

Interaction Types & Directionality: n/a

Interaction Info: Trial Name FP-1039 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

TdgClinicalTrial: FP-1039

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class fusion protein FDA Approval not approved

Publications:

TTD: FP-1039

Alternate Names: D0U2DO TTD Drug ID

Drug Info:

Publications: Szlachcic A et al., 2012, FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation., Int J Nanomedicine

JAX-CKB: GSK3052230

Alternate Names:

Drug Info:

Publications: Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med

TTD: GSK3052230

Alternate Names: D0P0LT TTD Drug ID

Drug Info:

Publications:

TALC: GSK3052230

Alternate Names: GSK3052230 Primary Drug Name GSK3052230 Drug Synonym FP-1039 Drug Synonym

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL4297755

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

Indication/Tumor Type lung cancer

PMIDs:
23226697 23536011

Sources:
TdgClinicalTrial JAX-CKB TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
23536011

Sources:
TdgClinicalTrial JAX-CKB

Interaction Types & Directionality:

suppressor (inhibitory)

Interaction Info:

Notes Targets other FGF ligands as well

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Drug Info:

Drug Indications antineoplastic agent

Drug Class fusion protein

FDA Approval not approved

Alternate Names:

D0U2DO TTD Drug ID

Publications:

Szlachcic A et al., 2012, FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation., Int J Nanomedicine

Publications:

Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med

Alternate Names:

D0P0LT TTD Drug ID

Alternate Names:

GSK3052230 Primary Drug Name

GSK3052230 Drug Synonym

FP-1039 Drug Synonym